OICR’s Drug Discovery Team is made up of 26 drug discovery scientists housed in state-of-art facilities with a mission to help Ontario’s researchers efficiently translate cancer related discoveries into novel oncology therapies. This team has “identified five of the most promising early stage oncology drug development projects in the province,” said Dr. Tom Hudson, the OICR’s president and scientific director. “OICR is pleased to support these Ontario-based research projects and we look forward to collaborating with our partners to help move them to the next stage of development,” he added.
The selected projects address a range of cancers, including hematological malignancies, triple negative breast cancer and colon cancer. They come from major institutions across Ontario and were selected from a province-wide call for proposals to identify promising oncology research that would benefit from OICR’s expertise in drug discovery.
Professor Juan Marchal Believes Propanc Biopharmas Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company appointed Ms. Belen Toledo MSc., a biotechnologist specializing in cell regenerative medicine, to evaluate the
Propanc Biopharma Provides Shareholder Update
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today on the progress of the Company, recent developments and forecast for 2021, as the Company prepares for entering clinical development for its lead product candidate, PRP, for the treatment and prevention of metastatic cancer. PRP represents a novel therapeutic approach, targeting and eradicating cancer stem cells, but leaving healthy stem cells alone, making it less toxic compared to current standard treatment options, like chemotherapy and radiotherapy. PRP does not suppress the immune system, and therefore in a post pandemic world, can offer support to cancer sufferers who are at risk of infection.